Get the Stockscreener App
0.00
100.00%
-8.68
After Hours:
8.69
8.69
+
Sage Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$8.68
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$543.56M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
0.00
EPS:
-8.39
Net Cash Flow:
$-424.74M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$8.82
52-Week Range:
$0.00
$10.74
Sage Therapeutics Inc Stock (SAGE) Company Profile
Name
Sage Therapeutics Inc
Sector
Industry
Phone
617-299-8380
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare SAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
0.00 | 543.56M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-25 | Resumed | BofA Securities | Underperform |
| Nov-21-24 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-04-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-29-24 | Initiated | Citigroup | Sell |
| May-29-24 | Initiated | Robert W. Baird | Neutral |
| Apr-17-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Aug-08-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-08-23 | Downgrade | Goldman | Buy → Neutral |
| Aug-08-23 | Downgrade | Needham | Buy → Hold |
| Aug-07-23 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-07-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-07-23 | Downgrade | Stifel | Buy → Hold |
| Aug-07-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Mar-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Mar-31-22 | Initiated | Berenberg | Hold |
| Nov-02-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-16-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-07-21 | Initiated | Piper Sandler | Overweight |
| Feb-26-21 | Downgrade | Mizuho | Buy → Neutral |
| Feb-25-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Resumed | Raymond James | Mkt Perform |
| Jan-22-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-04-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-04-20 | Upgrade | Mizuho | Neutral → Buy |
| Dec-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-06-20 | Reiterated | H.C. Wainwright | Neutral |
| Sep-11-20 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-10-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-08-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-28-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-06-19 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-05-19 | Reiterated | Guggenheim | Buy |
| Dec-05-19 | Downgrade | SunTrust | Buy → Hold |
| Oct-30-19 | Initiated | H.C. Wainwright | Neutral |
| May-23-19 | Initiated | Wedbush | Outperform |
| Apr-25-19 | Initiated | Jefferies | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-11-18 | Initiated | Oppenheimer | Outperform |
View All
Sage Therapeutics Inc Stock (SAGE) Latest News
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Supernus completes acquisition of Sage Therapeutics for $8.50 per share By Investing.com - Investing.com South Africa
Supernus completes acquisition of Sage Therapeutics for $8.50 per share - Investing.com Australia
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewswire
Supernus' $200M Sage Therapeutics Acquisition Adds First-Ever Oral Postpartum Depression Drug - Stock Titan
Sage Therapeutics 2025 Q2 Earnings Significant Revenue Growth as Net Income Loss Narrows 51.7% - AInvest
Sage Therapeutics Announces Second Quarter 2025 Financial Results - BioSpace
SAGE Therapeutics earnings beat by $0.15, revenue topped estimates - Investing.com Canada
Market reaction to Sage Therapeutics Inc.’s recent newsWeekly Stock Opportunity Radar Scanner Activated - metal.it
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
What are Sage Therapeutics Inc. company’s key revenue driversBeginner Investor Tips For 2025 - jammulinksnews.com
Cwm LLC Buys 58,410 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Why is Sage Therapeutics Inc. stock attracting strong analyst attentionEarnings Report Outlook For 2025 - jammulinksnews.com
SAGE Acquisition Advances as Antitrust Waiting Period Ends - GuruFocus
Supernus announces expiration of HSR waiting period for Sage Therapeutics - TipRanks
Supernus Pharmaceuticals Announces Expiration of - GlobeNewswire
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - Benzinga
Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan
Is it the right time to buy Sage Therapeutics Inc. stockFree Wealth Planning Blueprint - jammulinksnews.com
What institutional investors are buying Sage Therapeutics Inc. stockDiscover stocks with explosive growth potential - jammulinksnews.com
What makes Sage Therapeutics Inc. stock price move sharplyFree Stock Selection - jammulinksnews.com
Sage Therapeutics SAGE 2025Q2 Earnings Preview Upside Ahead on Revenue Growth - AInvest
What are analysts’ price targets for Sage Therapeutics Inc. in the next 12 monthsFree Stock Market Return Analysis - jammulinksnews.com
How strong is Sage Therapeutics Inc. company’s balance sheetGet expert analysis on top stock picks - jammulinksnews.com
What catalysts could drive Sage Therapeutics Inc. stock higher in 2025Access daily stock market expert updates - jammulinksnews.com
When is Sage Therapeutics Inc. stock expected to show significant growthExplosive trading growth - jammulinksnews.com
BML Capital Management LLC Takes Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Sage Therapeutics (SAGE) Expected to Announce Earnings on Wednesday - MarketBeat
Is Sage Therapeutics Inc. a good long term investmentOutstanding stock performance - PrintWeekIndia
What drives Sage Therapeutics Inc. stock priceUnbelievable profit margins - Autocar Professional
What analysts say about Sage Therapeutics Inc. stockFree Investment Community - Autocar Professional
Sage Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Sage Therapeutics Inc Stock (SAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):